University of Kentucky researchers reported that 14 days of treatment reduced microglia by about 87% in APP/PS1 mice with Alzheimer’s-like pathology and increased sleep by more than two hours per day. Amyloid plaque burden did not fall, suggesting that immune-cell responses contribute to sleep loss. The original study measured sleep with brain-wave recordings and distinguished aging from disease-related effects. These are mouse findings, not evidence of efficacy or safety in humans, and they do not establish long-term removal of protective brain immune cells as an appropriate treatment.